Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan With or Without Radiotherapy in HER2-positive Advanced Breast Cancer With Brain Metastases
NCT07100600Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2025
- Primary completion
- Jul 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab rezetecan in breast cancer (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Progression-Free Survival at 1.5 years. Started Aug 2025; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07100600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07100600.